Clinical Drug Investigation

, Volume 32, Supplement 2, pp 1–2 | Cite as

Sorafenib Use in Hepatocellular Carcinoma in Japan: Early Experience and Impact on Clinical Practice

  • Andrew X. Zhu


  1. 1.
    Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World journal of gastroenterology: WJG 2006; 12(5): 828–9PubMedGoogle Scholar
  2. 2.
    Ferlay J, Shin H, Bray F, Forman D, Mathers C and Parkin D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Available from URL: [Accessed: 2011 Nov 15]Google Scholar
  3. 3.
    American Cancer Society. What is liver cancer? Available from URL: [Accessed: 2011 Nov 15]
  4. 4.
    Easton A. Liver cancer toll high in Japan. British Medical Journal 1999; 318(7197): 1510PubMedCrossRefGoogle Scholar
  5. 5.
    El-Serag H, Rudolf K. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132(7): 2557–76PubMedCrossRefGoogle Scholar
  6. 6.
    Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treatment Reviews 2011; 37(3): 212–20PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Andrew X. Zhu
    • 1
  1. 1.Harvard Medical SchoolMassachusetts General Hospital Cancer CenterBostonUSA

Personalised recommendations